CGRP Inhibitor Market to Grow at 9.72% CAGR through 2030
Expanding applications beyond migraine treatment is
expected to drive the Global CGRP Inhibitor Market growth in the forecast
period, 2026-2030.
According to TechSci Research report, “CGRP
Inhibitor Market – Global Industry Size, Share, Trends, Competition,
Forecast & Opportunities, 2020-2030F”, the Global CGRP Inhibitor Market
stood at USD 3.29 Billion in 2024 and is expected to reach USD 4.87 Billion by
2030 with a CAGR of 9.72% during the forecast period.
An emerging trend in the Global CGRP Inhibitor Market
is the exploration of CGRP-targeting therapies for conditions beyond migraine
treatment. While CGRP inhibitors have proven efficacy in managing migraines,
researchers are now investigating their potential applications in various
neurological and inflammatory disorders. Studies suggest that CGRP plays a role
in other headache-related conditions, such as cluster headaches and trigeminal
neuralgia, both of which cause severe pain and have limited treatment options.
Given CGRP's involvement in pain signaling and neurogenic inflammation,
inhibitors targeting this pathway may offer significant relief to patients
suffering from these conditions.
Beyond headaches, CGRP inhibitors are being explored
for their therapeutic potential in chronic pain conditions such as fibromyalgia
and osteoarthritis. Fibromyalgia, a disorder characterized by widespread
musculoskeletal pain, has been linked to abnormal pain processing in the
nervous system, where CGRP modulation could provide symptom relief. Similarly,
in osteoarthritis, CGRP is associated with joint pain and inflammation, making
CGRP-targeting therapies a promising avenue for pain management. Preliminary
research indicates that CGRP inhibitors could help reduce inflammation and pain
in these conditions, expanding the scope of their clinical utility.
The role of CGRP in vascular diseases is
drawing attention from researchers and pharmaceutical companies. CGRP is a
potent vasodilator, meaning it influences blood vessel dilation and
circulation. This has led to investigations into its impact on conditions such
as hypertension, Raynaud's phenomenon, and even cardiovascular diseases. CGRP modulation is being studied for inflammatory disorders,
given its role in immune system regulation. As clinical evidence supporting
these applications continues to grow, pharmaceutical companies are expected to
pursue expanded indications, further driving innovation in the CGRP inhibitor
market. Over time, these developments will not only increase the therapeutic
reach of CGRP inhibitors but also foster significant market expansion.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global CGRP Inhibitor Market”
The Global CGRP Inhibitor Market is segmented into route
of administration, treatment, end user, regional distribution, and company.
Based on the Route of Administration, the Oral segment was the fastest-growing in the global CGRP Inhibitor Market in 2024. Oral medications are highly preferred due to their convenience and ease of use. Patients can take them with a simple glass of water, eliminating the need for injections or specialized equipment. This ease of use often leads to better patient compliance and adherence to treatment regimens. Additionally, oral administration is non-invasive, making it more comfortable and less intimidating for patients, while avoiding the pain and potential complications associated with intravenous injections or nasal administration. These factors are driving the rapid growth of the oral segment in the market.
Based on region, Europe is the second most dominant
region in the global CGRP inhibitor market, following North America. Several
factors contribute to its strong market presence, including an advanced
healthcare infrastructure, robust research capabilities, and a well-established
regulatory framework that supports the adoption of novel therapies. The region
has been at the forefront of medical innovation, facilitating the early
approval and widespread use of CGRP inhibitors for migraine treatment. The high
prevalence of migraine disorders across Europe has further driven demand for
effective treatment solutions. Recognizing the impact of migraines on both
individuals and healthcare systems, European nations have prioritized the
development and accessibility of CGRP inhibitors. This commitment has ensured
that patients receive innovative therapies designed to improve their quality of
life.
Europe’s emphasis on preventive
healthcare aligns with the therapeutic benefits of CGRP inhibitors, which help
reduce the frequency and severity of migraine attacks. This focus on long-term
health outcomes has encouraged healthcare providers to integrate these
treatments into standard migraine management protocols. The presence
of key pharmaceutical companies and research institutions has contributed to
the region’s competitive position. These entities continue to invest in
developing next-generation CGRP inhibitors, further strengthening Europe’s role
in the market. Europe’s strategic healthcare initiatives, strong regulatory
environment, and proactive approach to migraine management have positioned it
as the second most dominant region in the global CGRP inhibitor market,
following North America.
Major companies operating in Global CGRP
Inhibitor Market are:
- Eli
Lilly and Company
- Pfizer
Inc.
- Teva
Pharmaceutical Industries Ltd
- Amgen
Inc
- Novartis
AG
- Allergan
- Biohaven
Pharmaceutical Holding Company Ltd.
- Sun
Pharmaceutical Industries Ltd.
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“The increasing preference for oral CGRP inhibitors is
reshaping the Global CGRP Inhibitor Market, primarily due to enhanced patient
compliance and ease of administration. Traditionally, CGRP inhibitors were
administered as injectable monoclonal antibodies, which, while effective, posed
challenges related to patient adherence and administration discomfort. The
introduction of small-molecule oral CGRP receptor antagonists, such as
atogepant and rimegepant, has significantly improved accessibility, offering a convenient
alternative for patients who prefer non-injectable treatment options. Oral CGRP
inhibitors are particularly beneficial for individuals suffering from episodic
migraines, who may require as-needed treatment rather than long-term
prophylaxis. Unlike injectables, which are often used for chronic migraine
prevention, oral formulations provide flexibility in managing migraine symptoms
as they arise. This shift is contributing to increased adoption rates, as
patients and healthcare providers recognize the advantages of oral
administration in terms of ease of use and immediate symptom relief. Pharmaceutical
companies are capitalizing on this trend by investing in the development of
next-generation oral CGRP inhibitors with improved bioavailability and extended
efficacy. These advancements aim to enhance therapeutic outcomes while
minimizing side effects, further driving market penetration. As more oral CGRP
inhibitors receive regulatory approvals and enter global markets, the overall
adoption of CGRP-targeting therapies is expected to grow.,” said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“CGRP Inhibitor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Preventive, Acute), By Route of Administration (Oral, Nasal, Intravenous), By End-User (Hospitals, Pharmacies, Specialty Clinics) By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
CGRP Inhibitor Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global CGRP Inhibitor
Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com